In a first, scientists led by one of Indian-origin have discovered natural human antibodies that can neutralise and protect animals against three virulent ebola viruses, an advance that could lead to vaccines against the deadly disease.
The broadly neutralising natural human antibodies were discovered in the blood of a survivor of the 2013-16 ebola outbreak in Western Africa, which caused more than 11,000 deaths and infected over 29,000 people.
The blood was found to contain remarkable antibodies that block not just one strain of Ebola from infecting animal cells, but all five known strains -- Zaire, Bundibugyo, Sudan, Reston and Tai Forest, the researchers said.
Our discovery and characterisation of broadly neutralising human antibodies is an important step toward a single therapy that could treat or prevent infection caused by any known ebolavirus, said Kartik Chandran, professor at Albert Einstein College of Medicine, New York.
Previously, monoclonal antibodies -- which bind to and neutralide specific pathogens and toxins -- emerged as one of the most promising treatments for Ebola patients. However, the therapy targetted just one of the specific ebola virus and could not work against the others.
In the study, published in the journal Cell, the team found that two of the 349 monoclonal antibodies -- ADI-15878 and ADI-15742 -- from the Ebola survivor, potently neutralised infection by all five known ebolaviruses in tissue culture.
Both the antibodies were able to protect animals (mice and ferrets) that had been exposed to a lethal dose of the three major agents: ebola virus, Bundibugyo virus and Sudan virus.
The study also pinpointed the human genes that are the likely source of the immune cells that produce the two antibodies.
"We'd like to synthesise vaccine immunogens [proteins that trigger antibody production] that can elicit the same types of broadly protective antibodies in people," Chandran added.
--IANS
rt/ksk/vt
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
